<DOC>
	<DOCNO>NCT01422486</DOCNO>
	<brief_summary>Study TLK199.2107 multicenter , single arm , open-label Phase 2 study oral ezatiostat ( Telintra® ) patient lenalidomide ( Revlimid® ) refractory resistant , red blood cell ( RBC ) transfusion-dependent , Low Intermediate-1 IPSS risk , del5q Myelodysplastic Syndrome ( MDS ) .</brief_summary>
	<brief_title>Phase 2 Study Telintra® Deletion 5q Myelodysplastic Syndrome</brief_title>
	<detailed_description>Study TLK199.2107 multicenter , single arm , open-label Phase 2 study oral ezatiostat ( Telintra® ) patient lenalidomide ( Revlimid® ) refractory resistant , red blood cell ( RBC ) transfusion-dependent , Low Intermediate-1 IPSS risk , del5q Myelodysplastic Syndrome ( MDS ) . Independence red blood cell transfusion , improvement level red blood cell , white blood cell , platelet , response bone marrow evaluate . Patients receive start dose 2000 mg total daily dose divide dos ( 1000 mg orally twice daily three week ( 21 day ) therapy follow one-week ( 7 day ) therapy rest period four-week ( 28 day ) treatment cycle . Patients continue treatment documentation lack MDS response , MDS progression , unacceptable toxicity , patient withdrawal study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Primary de Novo MDS Low Intermediate1 IPSS risk MDS Deletion 5q chromosome [ del ( 5q ) MDS ] Refractory resistant lenalidomide ( Revlimid ) ECOG performance score 0 1 Documentation significant anemia without additional cytopenia Adequate kidney liver function Patients must discontinue hematopoietic growth factor least 3 week prior study entry Prior allogenic bone marrow transplant MDS Known sensitivity ezatiostat ( injection oral tablet ) Prior treatment hypomethylating agent ( HMA ) ( e.g. , azacitadine , decitabine ) History MDS IPSS risk score great 1.0 Pregnant lactate woman Any severe concurrent disease , infection comorbidity , judgement investigator , would make patient inappropriate study entry Oral steroid great 10 mg per day . Exceptions : prescribe condition ( new adrenal failure , asthma , arthritis ) brief steroid use ( tapered dose acute nonMDS condition ) History hepatitis B C , HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hematology</keyword>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Low risk MDS</keyword>
	<keyword>Intermediate-1 risk MDS</keyword>
	<keyword>Int-1 risk MDS</keyword>
	<keyword>Transfusion dependence</keyword>
	<keyword>Lenalidomide refractory</keyword>
	<keyword>Revlimid refractory</keyword>
	<keyword>Lenalidomide resistant</keyword>
	<keyword>Revlimid resistant</keyword>
	<keyword>Telintra</keyword>
	<keyword>ezatiostat</keyword>
	<keyword>ezatiostat hydrochloride</keyword>
	<keyword>TLK199</keyword>
	<keyword>Glutathione</keyword>
	<keyword>Glutathione analog</keyword>
	<keyword>Glutathione Transferase</keyword>
	<keyword>Glutathione Transferase P1-1 inhibitor</keyword>
	<keyword>GST P1-1 inhibitor</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Differentiation</keyword>
	<keyword>Enzyme inhibitor</keyword>
</DOC>